Telix Pharmaceuticals (TLX.AX) Earnings Analysis

Telix Pharmaceuticals (TLX.AX) next reports earnings on 2026-08-20, consensus EPS 0.05531 AUD. Last quarter (2026-02-19) it missed with EPS -0.01738 AUD vs 0.04911 AUD est (-135.4%). It has beaten estimates in 0/4 recent quarters (0%). Trailing P/E -472.59.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TLX.AX next report earnings?

Next earnings date2026-08-20
Consensus EPS estimate0.05531 AUD
Revenue estimate0.69B

TLX.AX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-19-0.01738 AUD0.04911 AUD-135.4%Miss
2025-08-20-0.01033 AUD0.203 AUD-105.1%Miss
2025-02-200.1108 AUD0.1462 AUD-24.2%Miss
2024-08-220.0333 AUD0.13 AUD-74.4%Miss

Beat rate: 0/4 (0%) over reported quarters with consensus data.

TLX.AX valuation and analyst view

Trailing P/E-472.59
Trailing EPS-0.03205 AUD
Price / book8.25
Dividend yield0.00%
Market cap5.03B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Telix Pharmaceuticals (TLX.AX)'s next earnings date?

Telix Pharmaceuticals is next scheduled to report on 2026-08-20, with a consensus EPS estimate of 0.05531 AUD and revenue estimate of 0.69B.

Did TLX.AX beat earnings last quarter?

In its 2026-02-19 report, TLX.AX posted EPS of -0.01738 AUD versus a 0.04911 AUD estimate — a miss of 135.4%.

What is TLX.AX's earnings track record?

Over the last 4 reported quarters with consensus data, TLX.AX beat estimates 0 times (0%).

What is TLX.AX's current P/E ratio and EPS?

TLX.AX trades at a trailing P/E of -472.59 on trailing EPS of -0.03205082384334284 AUD.

What do analysts rate TLX.AX?

TLX.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.